This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.
Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.
Old Dominion (ODFL) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Old Dominion's (ODFL) fourth-quarter 2019 results will likely reflect unfavorable impact of a soft freight environment.
Want To Retire Early? Learn the Intelligent Investing Secret - January 31, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Merck's Dificid Gets FDA Approval in Pediatric Indication
by Indrajit Bandyopadhyay
The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.
Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $86.10, marking a +0.14% move from the previous day.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Roche Submits Application for Tecentriq-Avastin Combo in HCC
by Zacks Equity Research
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Top Stock Analyst Reports for Merck, Broadcom & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Broadcom (AVGO) and Sanofi (SNY).
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
by Sweta Killa
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Roche's Urothelial Cancer Study on Tecentriq Disappoints
by Zacks Equity Research
Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
by Kinjel Shah
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
Signs That Your Trading Will Ruin Your Retirement - January 24, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
BioLineRx Concludes Recruitment in Pancreatic Cancer Study
by Zacks Equity Research
BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.
Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
by Zacks Equity Research
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short
by Zacks Equity Research
J&J (JNJ) comes up with mixed fourth-quarter 2019 results.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Is Merck & Co. (MRK) a Profitable Pick for Value Investors?
by Zacks Equity Research
Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.
Seattle Genetics Up More Than 40% in the Past Year: Here's Why
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.